Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors

Blockade of programmed cell death ligand‐1 with durvalumab has shown efficacy and safety in large, international studies of patients with advanced solid tumors. A phase 1, non‐randomized, open‐label multicenter study was initiated to evaluate durvalumab in a Japanese population. The first part of th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Fujiwara, Yutaka, Iguchi, Haruo, Yamamoto, Noboru, Hayama, Manabu, Nii, Masahiro, Ueda, Shinya, Komuro, Keiko, Sugimoto, Mariko, Vlahovic, Gordana, Kozuki, Toshiyuki
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6501043/
https://ncbi.nlm.nih.gov/pubmed/30891877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky